1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

RMAT Designation Requests May Rise Or Fall On Manufacturing Changes, Clinical Data Breadth

 
• By Sue Sutter

Product characterization questions and partial or inconsistent clinical data are among the more common reasons why the US FDA denies, or seeks additional information about, a request for regenerative medicine advanced therapy designation, FDA’s Bryan says; sponsors should consider why they are seeking designation when deciding whether to apply for RMAT, breakthrough therapy or both.

Yes no maybe Button over white Background
Whether FDA says 'yes' or 'no' to an RMAT designation request may depend upon changes to the product during development and the extent of clinical data provided on different outcomes.

Product characterization questions and partial or inconsistent clinical data are among the more common reasons why the US FDA denies, or seeks additional information about, a request for regenerative medicine advanced therapy (RMAT) designation, according to the head of the office that oversees the expedited pathway.

Manufacturing remains a focus of concern during the intensive interactions between the agency and sponsor upon receipt of RMAT designation,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

UniQure Is Latest Gene Therapy Sponsor Surprised By US FDA Reversal

 
• By Bridget Silverman

UniQure’s Huntington's disease filing plans are in disarray after the FDA reversed course on the company's regulatory strategy employing real-world evidence and accelerated approval.

UK’s ‘Bold’ New Rare Disease Rulebook Has Novel Licensing Pathway And Provisional Approvals

 
• By Eliza Slawther

The UK drug regulator is planning to introduce a “flexible, proportionate” licensing and registration model for rare diseases, which could see drugs granted provisional approvals based on “appropriate, albeit limited” evidence.

China Eyes First-In-Class Blockbuster Drugs In Display of ‘Strategic Purpose’

A new 10-year, government-supported R&D program in China will focus on new targets and emerging technologies which can be translated into first-in-class drugs and give birth to top players in the global pharma industry.

US Advanced Health Projects Agency Launches Personalized Medicine Push

 
• By Michael McCaughan

The ARPA-H program is making individualized genetic therapies a new research priority, including the “THRIVE” grant program, which will seek genetic platforms beyond AAV and CRISPR, and “GIVE,” which will support bedside manufacturing for RNA therapies.

More from Advanced Technologies

China Eyes First-In-Class Blockbuster Drugs In Display of ‘Strategic Purpose’

A new 10-year, government-supported R&D program in China will focus on new targets and emerging technologies which can be translated into first-in-class drugs and give birth to top players in the global pharma industry.

US Advanced Health Projects Agency Launches Personalized Medicine Push

 
• By Michael McCaughan

The ARPA-H program is making individualized genetic therapies a new research priority, including the “THRIVE” grant program, which will seek genetic platforms beyond AAV and CRISPR, and “GIVE,” which will support bedside manufacturing for RNA therapies.

US FDA Cell And Gene Therapy Regulation “Must Evolve,” OTP Acting Director Kumar Says

 
• By Michael McCaughan

The FDA cannot “rest on its laurels” when it comes to advancing cell and gene therapy regulatory advances, the acting head of the Office of Therapeutic Products said. Leveraging knowledge across programs could be a key.